Recombinant
RabMAb

Anti-Trefoil Factor 3 antibody [EPR3974] (ab108599)

Publishing research using ab108599? Please let us know so that we can cite the reference in this datasheet.

ab108599 has been referenced in 6 publications.

  • Yuan Z  et al. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer Cell Int 17:7 (2017). WB ; Human . PubMed: 28070169
  • Diao S  et al. Trefoil factor 3 contributes to the malignancy of glioma via regulating HIF-1a. Oncotarget 8:76770-76782 (2017). PubMed: 29100347
  • Chong QY  et al. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma. Oncotarget 8:74188-74208 (2017). PubMed: 29088778
  • You ML  et al. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget 8:39323-39344 (2017). PubMed: 28445151
  • Guo J  et al. MicroRNA-7-5p regulates the expression of TFF3 in inflammatory bowel disease. Mol Med Rep 16:1200-1206 (2017). PubMed: 28627600
  • Guo J  et al. MicroRNA-7-5p regulates the proliferation and migration of intestinal epithelial cells by targeting trefoil factor 3 via inhibiting the phosphoinositide 3-kinase/Akt signalling pathway. Int J Mol Med 40:1435-1443 (2017). PubMed: 28901375

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up